Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 299 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open- Monitoring Clear all
Completed Not applicable Interventional

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed Loop with Pramlintide
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 4 Interventional

Vogelxo(R) ABPM Study in Hypogandal Men

NCT04558567
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Vogelxo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Anaheim, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Micro-Clinic Obesity and Metabolic Risk Prevention Program

NCT01651065
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Heart Disease, Obesity, Hypertension, Dyslipidemia
Interventions
Microclinic Diabetes Education Program, Control
Behavioral
Lead sponsor
Microclinic International
Other
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pineville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Not applicable Interventional

Addressing Nocturnal Sleep/Wake Effects on Risk of Suicide in Older Adults

NCT04986007
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Suicidal Ideation
Interventions
Digital Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
MICHAEL A GRANDNER
Other
Eligibility
55 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

NCT02527343
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
volanesorsen, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Internet Delivered Parent Child Interaction Therapy

NCT05725525
View directory record Official record
Conditions
Disruptive Behavior
Interventions
Remote PCIT augmented with wearable devices
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Radical Openness for Adolescents Pilot

NCT05913557
View directory record Official record
Conditions
Anorexia Nervosa, Obsessive-Compulsive Disorder, Social Phobia, Depression, Anxiety
Interventions
Radically Open Dialectical Behavior Therapy (RO DBT)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Brief Smartphone Treatment Study

NCT04846777
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Mindfulness ecological momentary intervention, Self-monitoring placebo
Device
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 22, 2026, 5:11 AM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

NCT07808333
View directory record Official record
Conditions
Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions
Nicotinamide, Standard Glaucoma Therapy
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
4
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Behavioral Activation for Independence in Older Veterans

NCT05493241
View directory record Official record
Conditions
Functional Independence
Interventions
Behavioral Activation for Independence in Older Veterans (ACTIVaTE), Usual care
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

NCT03117569
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
glecaprevir (300mg)/pibrentasvir (120mg)
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 22, 2026, 5:11 AM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention

NCT06550804
View directory record Official record
Conditions
HIV Infections, Adherence, Medication
Interventions
A-TEAM
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

Aggrenox Prevention of Access Stenosis

NCT00067119
View directory record Official record
Conditions
Kidney Failure
Interventions
Aggrenox, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Iowa City, Iowa • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Exercise and Nutrition on Obese Microbiome

NCT04138303
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Exercise Protocol, Calorie-Restrictive Low Carbohydrate Diet (CR-LC), Ancestral Diet (AD)
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

NCT05988385
View directory record Official record
Conditions
Obstructive Sleep Apnea, Cognitive Decline
Interventions
Positive airway pressure, Oral appliance therapy, Positional therapy
Device
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
55 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Tucson, Arizona • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

NCT05114590
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Canyon Country, California • Huntington Park, California • Lomita, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Not applicable Interventional Results available

PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor

NCT03401489
View directory record Official record
Conditions
Blood Pressure, Hypertension, Mhealth
Interventions
PACESETTER
Device
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
San Francisco, California • Charleston, South Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Orthodontic Appliances Efficiency With Remote Dental Monitoring and Artificial Intelligence Algorithms

NCT05573308
View directory record Official record
Conditions
Malocclusion, Misaligned Teeth
Interventions
Clear Aligners with Dental Monitoring, Clear Aligners
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
12 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
4
States / cities
Antioch, Illinois • Chicago, Illinois • Grayslake, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

NCT04131413
View directory record Official record
Conditions
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions
pNGVL4aCRTE6E7L2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

NCT02862600
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Interventions
Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
Drug · Device
Lead sponsor
Heart Metabolics Limited
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Stanford, California • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

NCT02523131
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM, Medtronic insulin pump 640G
Device
Lead sponsor
University of Cambridge
Other
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 22, 2026, 5:11 AM EDT